PhoenixBio Co., Ltd. (JP:6190)
:6190
Want to see JP:6190 full AI Analyst Report?
6190 Stock Chart & Stats
¥484.00
¥9.00(2.79%)
At close: 4:00 PM EST
¥484.00
¥9.00(2.79%)
Day’s Range― - ―
52-Week Range¥352.00 - ¥724.00
Previous CloseN/A
Volume3.50K
Average Volume (3M)360.67K
Market Cap
¥1.80B
Enterprise Value¥1.22B
Total Cash (Recent Filing)¥1.04B
Total Debt (Recent Filing)¥503.59M
Price to Earnings (P/E)6.1
Beta0.54
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-112.33
Shares Outstanding4,076,933
10 Day Avg. Volume91,460
30 Day Avg. Volume360,670
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.97
P/FCF Ratio-15.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Niche Business ModelPhoenixBio's focus on specialized disease-model animals and integrated preclinical services creates durable demand from pharma and academia. This niche reduces competition, supports recurring contracts and technical stickiness, and aligns with sustained R&D spending in drug discovery over months to years.
Relatively Stable Balance SheetA stable equity base and moderate leverage lower refinancing and liquidity risk over the medium term. This financial stability supports capital-intensive facility maintenance and compliance needs for animal research, allowing the company to operate through revenue cycles without immediate reliance on dilutive funding.
Positive Revenue Trend And Historical Gross MarginsReported positive revenue growth alongside historically strong gross margins indicates the business can earn healthy unit economics on core sales. Even with recent volatility, sustained top-line expansion and historically solid gross margins support long-term service viability and reinvestment capacity.
Bears Say
Negative Operating Cash FlowPersistent negative operating and free cash flows constrain the company's ability to fund operations, maintain facilities, and invest in growth without external financing. Over a 2-6 month horizon this raises risks that capital needs force cost cuts, asset sales, or dilutive funding.
Ongoing Negative ProfitabilityNegative operating and net margins reflect structural cost or revenue challenges that impair earnings sustainability. If unaddressed, this reduces retained earnings, limits reinvestment, and increases dependency on financing, threatening margin recovery prospects across the medium term.
Declining Revenues / Financial PressureReported declining revenues alongside profit and cash generation issues signal weakening demand or competitive pressure. Continued top-line contraction undermines operating leverage, making it harder to cover fixed costs of specialized facilities and threatening medium-term revenue resilience.
6190 FAQ
What was PhoenixBio Co., Ltd.’s price range in the past 12 months?
PhoenixBio Co., Ltd. lowest stock price was ¥352.00 and its highest was ¥724.00 in the past 12 months.
What is PhoenixBio Co., Ltd.’s market cap?
PhoenixBio Co., Ltd.’s market cap is ¥1.80B.
When is PhoenixBio Co., Ltd.’s upcoming earnings report date?
PhoenixBio Co., Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 94 days.
How were PhoenixBio Co., Ltd.’s earnings last quarter?
PhoenixBio Co., Ltd. released its earnings results on May 15, 2026. The company reported ¥7.866 earnings per share for the quarter, beating the consensus estimate of N/A by ¥7.866.
Is PhoenixBio Co., Ltd. overvalued?
According to Wall Street analysts PhoenixBio Co., Ltd.’s price is currently Overvalued.
Does PhoenixBio Co., Ltd. pay dividends?
PhoenixBio Co., Ltd. does not currently pay dividends.
What is PhoenixBio Co., Ltd.’s EPS estimate?
PhoenixBio Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PhoenixBio Co., Ltd. have?
PhoenixBio Co., Ltd. has 4,076,933 shares outstanding.
What happened to PhoenixBio Co., Ltd.’s price movement after its last earnings report?
PhoenixBio Co., Ltd. reported an EPS of ¥7.866 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.778%.
Which hedge fund is a major shareholder of PhoenixBio Co., Ltd.?
Currently, no hedge funds are holding shares in JP:6190
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.
Technical Analysis
Trans Genic Inc.
―
Takara Bio Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―